Health-Care Stocks Plunge Amid Growing Scrutiny of Pharmacy Benefit Managers

Shares of prominent health-care companies, including UnitedHealth Group, Cigna, and CVS Health, experienced significant declines on Wednesday, dropping as much as 5%. This downturn followed rising investor concerns about potential changes in the industry, particularly with regard to Pharmacy Benefit Managers (PBMs). These companies, which are among the largest private health insurers and PBM operators in the United States, saw their stocks hit hard as lawmakers and regulators intensify efforts to reform the PBM sector.

The latest declines in stock prices are tied to bipartisan legislation introduced in Congress, which aims to address long-standing concerns about the influence of PBMs in the drug market. UnitedHealth, Cigna, and CVS Health, which also own pharmacy businesses, are at the heart of the debate surrounding the rising costs of prescription drugs and the role PBMs play in the supply chain. All three companies experienced a drop of at least 5% in their stock value on Wednesday.

The new legislation, introduced by Senators Elizabeth Warren (D-Mass.) and Josh Hawley (R-Mo.), proposes significant changes to the PBM industry. The bill seeks to force companies that own both health insurers and PBMs to divest their pharmacy operations within three years. The intention is to curb concerns that PBMs have inflated drug prices and manipulated the market for profit—a practice that has long been criticized by lawmakers and regulators alike.

Senator Warren, a leading advocate of the bill, voiced strong disapproval of PBM practices. “PBMs have manipulated the market to enrich themselves—hiking up drug costs, cheating employers, and driving small pharmacies out of business,” she stated. “My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen.”

At the core of the legislation is the belief that PBMs’ ownership of both health insurers and pharmacies creates a fundamental conflict of interest. This conflict allows health-care companies to maximize profits at the expense of patients and independent pharmacies, critics argue. Public pressure has mounted in recent years, with ongoing investigations into PBM practices by the Federal Trade Commission (FTC), which has been examining the role of PBMs in driving up drug prices since 2022.

Currently, the three largest PBMs—Optum Rx (owned by UnitedHealth Group), Caremark (owned by CVS Health), and Express Scripts (owned by Cigna)—control approximately 80% of the nation’s prescription drug market. These PBMs play a pivotal role in negotiating drug rebates with manufacturers, managing formularies, and reimbursing pharmacies for prescriptions. However, their practices have been under fire for fostering a lack of transparency in drug pricing, often benefiting the PBMs at the expense of consumers.

The introduction of this legislation coincides with a difficult period for the health-care sector, which has been grappling with a series of challenges. In particular, the tragic death of Brian Thompson, the CEO of UnitedHealth Group’s insurance division, has cast a pall over the industry. In the wake of his death, health-care stocks had already been on a downward trajectory, and the introduction of PBM reform legislation has only heightened investor concerns.

As the debate surrounding PBMs continues to intensify, the future of major health-care companies remains uncertain. Lawmakers are increasingly pushing for reforms, and the health-care industry is bracing for significant changes in the way PBMs operate within the U.S. drug supply chain. With growing public criticism and mounting legislative pressure, the health-care sector must now navigate the challenges ahead as it adapts to a potentially shifting landscape.

For feedback: contact the BATV Editorial Division at: info@batvja.com